Abstract
The development of bacterial resistance against current antibiotic drugs necessitates a continuous renewal of the arsenal of efficacious drugs. This imperative has not been met by the output of antibiotic research and development of the past decades for various reasons, including the declining efforts of large pharma companies in this area. Moreover, the majority of novel antibiotics are chemical derivatives of existing structures that represent mostly step innovations, implying that the available chemical space may be exhausted. This review negates this impression by showcasing recent achievements in lead finding and optimization of antibiotics that have novel or unexplored chemical structures. Not surprisingly, many of the novel structural templates like teixobactins, lysocin, griselimycin, or the albicidin/cystobactamid pair were discovered from natural sources. Additional compounds were obtained from the screening of synthetic libraries and chemical synthesis, including the gyrase-inhibiting NTBI’s and spiropyrimidinetrione, the tarocin and targocil inhibitors of wall teichoic acid synthesis, or the boronates and diazabicyclo[3.2.1]octane as novel β-lactamase inhibitors. A motif that is common to most clinically validated antibiotics is that they address hotspots in complex biosynthetic machineries, whose functioning is essential for the bacterial cell. Therefore, an introduction to the biological targets—cell wall synthesis, topoisomerases, the DNA sliding clamp, and membrane-bound electron transport—is given for each of the leads presented here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguilaniu H, Durieux J, Dillin A (2005) Metabolism, ubiquinone synthesis, and longevity. Genes Dev 19:2399–2406. doi:10.1101/gad.1366505
Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565–1574. doi:10.1021/bi5000564
Alm RA, Lahiri SD, Kutschke A et al (2015) Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59:1478–1486. doi:10.1128/AAC.04456-14
Amaral L, Martins A, Spengler G, Molnar J (2014) Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol 4:Article168. doi:10.3389/fphar.2013.00168
Anderson VE, Osheroff N (2001) Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7:337–353. doi:10.2174/1381612013398013
Anderson RJ, Groundwater PW, Todd A, Worsley AJ (2012) Antibacterial agents: chemistry, mode of action, mechanisms of resistance and clinical applications. Wiley, New York
Argiriadi MA, Goedken ER, Bruck I, et al (2006) Crystal structure of a DNA polymerase sliding clamp from a Gram-positive bacterium. BMC Struct Biol 6:2. doi:10.1186/1472-6807-6-2
Askoura M, Mottawea W, Abujamel T, Taher I (2011) Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med 6:1–8. doi:10.3402/ljm.v6i0.5870
Atilano ML, Pereira PM, Yates J et al (2010) Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus. Proc Natl Acad Sci USA 107:18991–18996. doi:10.1073/pnas.1004304107
Baltrus DA (2013) Exploring the costs of horizontal gene transfer. Trends Ecol Evol 28:489–495. doi:10.1016/j.tree.2013.04.002
Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8:557–563. doi:10.1016/j.coph.2008.04.008
Basarab GS, Manchester JI, Bist S et al (2013) Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J Med Chem 56:8712–8735. doi:10.1021/jm401208b
Basarab GS, Kern GH, McNulty J et al (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep 5:11827. doi:10.1038/srep11827
Bates AD, Maxwell A (2007) Energy coupling type II topoisomerase why do they hydrolyze ATP? Biochemistry 46:7929–7941. doi:10.1021/bi700789g
Bauer A, Brönstrup M (2014) Industrial natural product chemistry for drug discovery and development. Nat Prod Rep 31:35–60. doi:10.1039/c3np70058e
Bauer R, Dicks LMT (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol 101:201–216. doi:10.1016/j.ijfoodmicro.2004.11.007
Baumann S, Herrmann J, Raju R et al (2014) Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew Chem Int Ed 53:14605–14609. doi:10.1002/anie.201409964
Bax BD, Chan PF, Eggleston DS et al (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940. doi:10.1038/nature09197
Bénazet et al (1966) Antibiotics—advances in research, production and clinical use. In: Herold M, Gabriel Z (eds) Proceedings of the congress on antibiotics held in Prague, 15–19 June, 1964. Butterworths, London, pp 262–264
Bengtsson B, Greko C (2014) Antibiotic resistance–consequences for animal health, welfare, and food production. Ups J Med Sci 119:96–102. doi:10.3109/03009734.2014.901445
Bérdy J (2012) Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot 65:441. doi:10.1038/ja.2012.54
Berleman J, Auer M (2013) The role of bacterial outer membrane vesicles for intra- and interspecies delivery. Environ Microbiol 15:347–354. doi:10.1111/1462-2920.12048
Bierbaum G, Sahl HG (1985) Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch Microbiol 141:249–254. doi:10.1007/BF00408067
Birch RG, Patil SS (1987a) Correlation between albicidin production and chlorosis induction by Xanthomonas albilineans, the sugarcane leaf scald pathogen. Physiol Mol Plant Pathol 30:199–206. doi:10.1016/0885-5765(87)90033-6
Birch RG, Patil SS (1987b) Evidence that an albicidin-like phytotoxin induces chlorosis in sugarcane leaf scald disease by blocking plastid DNA replication. Physiol Mol Plant Pathol 30:207–214. doi:10.1016/0885-5765(87)90034-8
Biswas S, Brunel J-M, Dubus J-C et al (2012) Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917–934. doi:10.1586/eri.12.78
Blair JMA, Richmond GE, Piddock LJV (2014) Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol 9:1165–1177. doi:10.2217/fmb.14.66
Bloom LB (2009) Loaing clamps for DNA replication and repair. DNA Repair 8:570–578. doi:10.1016/j.dnarep.2008.12.014.Loading
Blunt JW, Copp BR, Munro MHG et al (2011) Marine natural products. Nat Prod Rep 28:196–268. doi:10.1039/c005001f
Boneca IG, Chiosis G (2003) Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opin Ther Targets 7:311–328. doi:10.1517/14728222.7.3.311
Bouchaudon J (1964) Nouveau cyclopeptide, sa préparation et les médicaments qui le contiennent
Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. doi:10.1086/595011
Boucher HW, Talbot GH, Benjamin DK et al (2013) 10 x ′20 Progress–development of new drugs active against gram-negative bacilli: an update from the Infectious diseases society of America. Clin Infect Dis 56:1685–1694. doi:10.1093/cid/cit152
Bozdogan B, Appelbaum PC (2004) Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23:113–119. doi:10.1016/j.ijantimicag.2003.11.003
Breu F, Guggenbichler S, Wollmann J (2001) Human as the world’s greatest evolutionary force. Science 293:1786–1790
Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5:321–332. doi:10.1038/nrd2004
Brötz H, Josten M, Wiedemann I et al (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30:317–327. doi:10.1046/j.1365-2958.1998.01065.x
Brötz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr Opin Pharmacol 8:564–573. doi:10.1016/j.coph.2008.06.008
Brown S, Xia G, Luhachack LG et al (2012) Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids. Proc Natl Acad Sci USA 109:18909–18914. doi:10.1073/pnas.1209126109
Brown S, Santa Maria JP, Walker S (2013) Wall teichoic acids of gram-positive bacteria. Annu Rev Microbiol 67:313–336. doi:10.1146/annurev-micro-092412-155620
Brown DG, Lister T, May-Dracka TL (2014) New natural products as new leads for antibacterial drug discovery. Bioorg Med Chem Lett 24:413–418. doi:10.1016/j.bmcl.2013.12.059
Brown L, Wolf JM, Prados-Rosales R, Casadevall A (2015) Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol 13:620–630. doi:10.1038/nrmicro3480
Bunting KA, Roe SM, Pearl LH (2003) Structural basis for recruitment of translesion DNA polymerase Pol IV/DinB to the β-clamp. EMBO J 22:5883–5892. doi:10.1093/emboj/cdg568
Burnouf DY, Olieric V, Wagner J et al (2004) Structural and biochemical analysis of sliding clamp/ligand interactions suggest a competition between replicative and translesion DNA polymerases. J Mol Biol 335:1187–1197. doi:10.1016/j.jmb.2003.11.049
Bush K (2010) Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 14:224. doi:10.1186/cc8892
Bush K (2015) Investigational agents for the treatment of Gram-negative bacterial infections: a reality check. ACS Infect Dis 1:509–511. doi:10.1021/acsinfecdis.5b00100
Butler EK, Davis RM, Bari V et al (2013a) Structure-function analysis of MurJ reveals a solvent-exposed cavity containing residues essential for peptidoglycan biogenesis in Escherichia coli. J Bacteriol 195:4639–4649. doi:10.1128/JB.00731-13
Butler MS, Blaskovich MA, Cooper MA (2013b) Antibiotics in the clinical pipeline in 2013. J Antibiot 66:571–591. doi:10.1038/ja.2013.86
Butler MS, Robertson AAB, Cooper MA (2014) Natural product and natural product derived drugs in clinical trials. Nat Prod Rep 31:1612–1661. doi:10.1039/c4np00064a
Campbell J, Singh AK, Swoboda JG et al (2012) An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in Staphylococcus aureus. Antimicrob Agents Chemother 56:1810–1820. doi:10.1128/AAC.05938-11
Carattoli A (2013) Plasmids and the spread of resistance. Int J Med Microbiol 303:298–304. doi:10.1016/j.ijmm.2013.02.001
Casacuberta E, Gonzalez J (2013) The impact of transposable elements in environmental adaptation. Mol Ecol 22:1503–1517. doi:10.1111/mec.12170
Cervellati R, Greco E (2016) In vitro antioxidant activity of ubiquinone and ubiquinol, compared to vitamin E. Helv Chim Acta 99:41–45. doi:10.1002/hlca.201500124
Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413. doi:10.1161/01.RES.0000255691.76142.4a
Chan WC, Bycroft BW, Lian L-Y, Roberts GCK (1989) Isolation and characterisation of two degradation products derived from the peptide antibiotic nisin. FEBS Lett 252:29–36. doi:10.1016/0014-5793(89)80884-1
Chen Q, Duan F, Li X et al (2014) Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase i. J Med Chem 57:3707–3714. doi:10.1021/jm401685f
Cho WK, Jergic S, Kim D et al (2014) Loading dynamics of a sliding DNA clamp. Angew Chem Int Ed 53:6768–6771. doi:10.1002/anie.201403063
Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260. doi:10.1128/MMBR.65.2.232
Chopra S, Matsuyama K, Tran T et al (2012) Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother 67:415–421. doi:10.1093/jac/dkr449
Chung BC, Zhao J, Gillespie RA et al (2013) Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis. Science 341:1012–1016. doi:10.1126/science.1236501
Clardy J, Fischbach MA, Walsh CT (2006) New antibiotics from bacterial natural products. Nat Biotechnol 24:1541–1550. doi:10.1038/nbt1266
Cleveland J, Montville TJ, Nes IF, Chikindas ML (2001) Bacteriocins: Safe, natural antimicrobials for food preservation. Int J Food Microbiol 71:1–20. doi:10.1016/S0168-1605(01)00560-8
Coates AR, Halls G, Hu Y (2011) Novel classes of antibiotics or more of the same? Br J Pharmacol 163:184–194. doi:10.1111/j.1476-5381.2011.01250.x
Cociancich S, Pesic A, Petras D et al (2015) The gyrase inhibitor albicidin consists of p-aminobenzoic acids and cyanoalanine. Nat Chem Biol 11:195–197. doi:10.1038/nchembio.1734
Cohen GN (2011) Microbial biochemistry, 2nd edn. Springer, Heidelberg
Cole ST, Riccardi G (2011) New tuberculosis drugs on the horizon. Curr Opin Microbiol 14:570–576. doi:10.1016/j.mib.2011.07.022
Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl Microbiol Biotechnol 92:479–497. doi:10.1007/s00253-011-3557-z
Connor EE (1998) Sulfonamide antibiotics. Prim Care Update Ob Gyns 5:32–35
Costenaro L, Grossmann JG, Ebel C, Maxwell A (2007) Modular structure of the full-length DNA gyrase B subunit revealed by small-angle X-ray scattering. Structure 15:329–339. doi:10.1016/j.str.2007.01.013
Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta-Gen Subj 1830:3670–3695. doi:10.1016/j.bbagen.2013.02.008
Czaplewski L, Bax R, Clokie M et al (2016) Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:239–251. doi:10.1016/S1473-3099(15)00466-1
D’Costa VM, King CE, Kalan L et al (2011) Antibiotic resistance is ancient. Nature 477:457–461. doi:10.1038/nature10388
D’Elia MA, Millar KE, Beveridge TJ, Brown ED (2006a) Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis. J Bacteriol 188:8313–8316. doi:10.1128/JB.01336-06
D’Elia MA, Pereira MP, Chung YS et al (2006b) Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J Bacteriol 188:4183–4189. doi:10.1128/JB.00197-06
D’Elia MA, Henderson JA, Beveridge TJ et al (2009a) The N-acetylmannosamine transferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 191:4030–4034. doi:10.1128/JB.00611-08
D’Elia MA, Pereira MP, Brown ED (2009b) Are essential genes really essential? Trends Microbiol 17:433–438. doi:10.1016/j.tim.2009.08.005
Dalrymple BP, Kongsuwan K, Wijffels G et al (2001) A universal protein-protein interaction motif in the eubacterial DNA replication and repair systems. Proc Natl Acad Sci U S A 98:11627–11632. doi:10.1073/pnas.191384398
Davies J (2006) Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 17:287–290
Davis BD (1987) Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51:341–350 doi:0146-0749/87/030341-10$02.00/0
de Kruijff B, van Dam V, Breukink E (2008) Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics. Prostaglandins Leukot Essent Fat Acids 79:117–121. doi:10.1016/j.plefa.2008.09.020
Debnath J, Siricilla S, Wan B et al (2012) Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem 55:3739–3755. doi:10.1021/jm201608g
Dhiman RK, Mahapatra S, Slayden RA et al (2009) Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72:85–97. doi:10.1111/j.1365-2958.2009.06625.x
Diez J, Martinez JP, Mestres J et al (2012) Myxobacteria: natural pharmaceutical factories. Microb Cell Fact 11:52–54. doi:10.1186/1475-2859-11-52
Donnell MO, Langston L, Stillman B et al (2013) Principles and concepts of DNA replication in bacteria, archea, and eukarya. Cold Spring Harb Perspect Biol 5:a010180. doi:10.1101/cshperspect.a010108
Doroghazi JR, Albright JC, Goering AW et al (2014) A roadmap for natural product discovery based on large-scale genomics and metabolomics. Nat Chem Biol 10:963–968. doi:10.1038/nchembio.1659
Dougherty TJ, Nayar A, Newman JV et al (2014) NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with Gram-negative antibacterial activity and in vivo efficacy. Antimicrob Agents Chemother. doi:10.1128/aac.02778-13
Dubée V, Chau F, Arthur M et al (2011) The in vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalis. Antimicrob Agents Chemother 55:910–912. doi:10.1128/AAC.01230-10
Edwards DI (1993) Nitroimidazole drugs–action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9–20. doi:10.1093/jac/31.1.9
Ehmann DE, Lahiri SD (2014) Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Curr Opin Pharmacol 18:76–83. doi:10.1016/j.coph.2014.09.007
Eichberg MJ (2015) Public funding of clinical-stage antibiotic development in the United States and European Union. Heal Secur 13:156–165. doi:10.1089/hs.2014.0081
Elshahawi SI, Shaaban KA, Kharel MK, Thorson JS (2015) A comprehensive review of glycosylated bacterial natural products. Chem Soc Rev 44:7591–7697. doi:10.1039/C4CS00426D
Epand RM, Walker C, Epand RF, Magarvey NA (2016) Molecular mechanisms of membrane targeting antibiotics. BBA Biomembranes 1858:980–987. doi:10.1016/j.bbamem.2015.10.018
European Centre for Disease Prevention and Control (2012) Annual report of the European antimicrobial resistance surveilance network (EARS-Net). ECDC, Stockholm
Farha MA, Leung A, Sewell EW et al (2013) Inhibition of WTA synthesis blocks the cooperative action of pbps and sensitizes MRSA to β-lactams. ACS Chem Biol 8:226–233. doi:10.1021/cb300413m
Finn J (2013) Evaluation of WO2012177707 and WO2012097269: Vertex’s phosphate prodrugs of gyrase and topoisomerase antibacterial agents. Expert Opin Ther Pat 23:1233–1237. doi:10.1517/13543776.2013.820707
Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science 325:1089–1093. doi:10.1126/science.1176667
Floss HG, Yu T-W (2005) Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 105:621–632. doi:10.1021/cr030112j
Forsberg KJ, Reyes A, Wang B et al (2012) The shared antibiotic resistome of soil bacteria and human pathogens. Science 337:1107–1111. doi:10.1126/science.1220761
Frankel RB, Kalmijn AJ, Amann R et al (2006) Sampling the antibiotic resistome. Science 311:374–378. doi:10.1126/science.1120800
Fujimoto N, Kosaka T, Yam M (2012) Menaquinone as well as ubiquinone as a crucial component in the Escherichia coli respiratory chain. In: Ekinci D (ed) Chemical biology, pp 187–208
Georgescu RE, Kim SS, Yurieva O et al (2008a) Structure of a sliding clamp on DNA. Cell 132:43–54. doi:10.1016/j.cell.2007.11.045
Georgescu RE, Yurieva O, Kim S-S et al (2008b) Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp. Proc Natl Acad Sci USA 105:11116–11121. doi:10.1073/pnas.0804754105
Gerth K, Pradella S, Perlova O et al (2003) Myxobacteria: Proficient producers of novel natural products with various biological activities—past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol 106:233–253. doi:10.1016/j.jbiotec.2003.07.015
Gibbons S (2004) Anti-staphylococcal plant natural products. Nat Prod Rep 21:263–277. doi:10.1039/b212695h
Giguère S (2013) Lincosamides, pleuromutilins, and streptogramins. Antimicrob Ther Vet Med 199–210. doi:10.1016/0007-1935(89)90107-3
Gilbert GL (2015) Knowing when to stop antibiotic therapy. Med J Aust 202:121–123. doi:10.5694/mja14.01201
Gillings MR (2013) Evolutionary consequences of antibiotic use for the resistome, mobilome, and microbial pangenome. Front Microbiol 4:1–10. doi:10.3389/fmicb.2013.00004
Godtfredsen WO, Jahnsen S, Lorck H et al (1962) Fusidic acid: a new antibiotic. Nature 193:987
Górska A, Sloderbach A, Marszałł MP (2014) Siderophore-drug complexes: Potential medicinal applications of the “Trojan horse” strategy. Trends Pharmacol Sci 1–8. doi:10.1016/j.tips.2014.06.007
Gubaev A, Klostermeier D (2014) Reprint of “the mechanism of negative DNA supercoiling: a cascade of DNA-induced conformational changes prepares gyrase for strand passage”. DNA Repair (Amst) 20:130–141. doi:10.1016/j.dnarep.2014.06.006
Gui W-J, Lin S-Q, Chen Y-Y et al (2011) Crystal structure of DNA polymerase III β sliding clamp from Mycobacterium tuberculosis. Biochem Biophys Res Commun 405:272–277. doi:10.1016/j.bbrc.2011.01.027
Hamamoto H, Urai M, Ishii K et al (2014) Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat Chem Biol 11:127–133. doi:10.1038/nchembio.1710
Hammes WP, Neuhaus FC (1974) On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari. Antimicrob Agents Chemother 6:722–728. doi:10.1128/AAC.6.6.722
Harrison E, Brockhurst MA (2012) Plasmid-mediated horizontal gene transfer is a coevolutionary process. Trends Microbiol 20:262–267. doi:10.1016/j.tim.2012.04.003
Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14:111–129. doi:10.1038/nrd4510
Hashimi SM, Wall MK, Smith AB et al (2007) The phytotoxin albicidin is a novel inhibitor of DNA gyrase. Antimicrob Agents Chemother 51:181–187. doi:10.1128/AAC.00918-06
Hawkey PM, Livermore DM (2012) Carbapenem antibiotics for serious infections. BMJ 344:1–7. doi:10.1136/bmj.e3236
Hawser S, Lociuro S, Islam K (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71:941–948. doi:10.1016/j.bcp.2005.10.052
Hecker SJ, Reddy KR, Totrov M et al (2015) Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682–3692. doi:10.1021/acs.jmedchem.5b00127
Heide L (2014) New aminocoumarin antibiotics as gyrase inhibitors. Int J Med Microbiol 304:31–36. doi:10.1016/j.ijmm.2013.08.013
Henry RJ (1943) The mode of action of sulfonamides. Bacteriol Rev 7:175–262. doi:10.1128/AEM.02766-10
Herrmann J, Lukežič T, Kling A, et al (2016) Strategies for the discovery and development of new antibiotics from natural products: three case studies. Curr Top Microbiol Immunol
Hesterkamp T (2016) Antibiotics clinical development and pipeline. Curr Top Microbiol Immunol. doi:10.1007/82_2015_451
Hiratsuka T, Furihata K, Ishikawa J et al (2008) An alternative menaquinone biosynthetic pathway operating in microorganisms. Science 321:1670–1673. doi:10.1126/science.1160446
Hirsch EB, Ledesma KR, Chang KT et al (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757. doi:10.1128/AAC.05927-11
Holzgrabe U (2015) New griselimycins for treatment of tuberculosis. Chem Biol 22:981–982. doi:10.1016/j.chembiol.2015.08.002
Hooper DC, Wolfson JS, McHugh GL et al (1982) Effects of novobiocin, coumermycin-a1, clorobiocin, and their analogs on Escherichia-coli Dna gyrase and bacterial-growth. Antimicrob Agents Chemother 22:662–671
Hsu S-TD, Breukink E, Tischenko E et al (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11:963–967. doi:10.1038/nsmb830
Huang G, Zhang L, Birch RG (2001) A multifunctional polyketide-peptide synthetase essential for albicidin biosynthesis in Xanthomonas albilineans. Microbiology 147:631–642
Jacobsson S, Golparian D, Alm RA et al (2014) High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585–5588. doi:10.1128/AAC.03090-14
Jacoby GA (2005) Mechanisms of bacterial resistance to quinolones. 41:S120–S126
Jad YE, Acosta GA, Naicker T et al (2015) Synthesis and biological evaluation of a teixobactin analogue. Org Lett 17:6182–6185. doi:10.1021/acs.orglett.5b03176
Ji C, Juárez-Hernández RE, Miller MJ (2012) Exploiting bacterial iron acquisition: siderophore conjugates. Future Med Chem 4:297–313. doi:10.4155/fmc.11.191
Jia Z, O’Mara ML, Zuegg J et al (2013) Vancomycin: ligand recognition, dimerization and super-complex formation. FEBS J 280:1294–1307. doi:10.1111/febs.12121
Johnston CW, Magarvey NA (2015) Natural products: untwisting the antibiotic’ome. Nat Chem Biol 11:177–178. doi:10.1038/nchembio.1757
Johnston CW, Skinnider MA, Dejong CA et al (2016) Assembly and clustering of natural antibiotics guides target identification. Nat Chem Biol 12:233–239. doi:10.1038/nchembio.2018
Johnstone TC, Nolan EM (2015) Beyond iron: non-classical biological functions of bacterial siderophores. Dalton Trans 44:6320–6339. doi:10.1039/c4dt03559c
Jolles G (1971) New cyclopeptides, GB Patent 1,252,553
Kahne D, Leimkuhler C, Lu W, Walsh C (2005) Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105:425–448. doi:10.1021/cr030103a
Kåhrström CT (2015) Antimicrobials: a new drug for resistant bugs. Nat Rev Microbiol 13:126–127. doi:10.1038/nrmicro3429
Kale MG, Raichurkar A, Shahul Hameed P et al (2013) Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA gyrase B. J Med Chem 56:8834–8848. doi:10.1021/jm401268f
Kale RR, Kale MG, Waterson D et al (2014) Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. Bioorg Med Chem Lett 24:870–879. doi:10.1016/j.bmcl.2013.12.080
Kalman D, Barriere S (1990) Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J 17:203–215
Kannan K, Mankin AS (2011) Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann N Y Acad Sci 1241:33–47. doi:10.1111/j.1749-6632.2011.06315.x
Kawamukai M (2002) Biosynthesis, Bioproduction and Novel Roles of Ubiquinone. J Biosci Bioeng 94:511–517
Keller S, Schadt HS, Ortel I, Süssmuth RD (2007) Action of atrop-abyssomicin C as an inhibitor of 4-amino-4-deoxychorismate synthase PabB. Angew Chem Int Ed 46:8284–8286. doi:10.1002/anie.200701836
Kern G, Palmer T, Ehmann DE, et al (2015) Inhibition of Neisseria gonorrhoeae type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. J Biol Chem M115.663534. doi:10.1074/jbc.M115.663534
Kirst HA (2013) Developing new antibacterials through natural product research. Expert Opin Drug Discov 8:479–493. doi:10.1517/17460441.2013.779666
Kjelstrup S, Hansen PMP, Thomsen LE et al (2013) Cyclic Peptide Inhibitors of the β-Sliding Clamp in Staphylococcus aureus. PLoS ONE. doi:10.1371/journal.pone.0072273
Kling A, Lukat P, Almeida DV et al (2015) Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348:1106–1112. doi:10.1126/science.aaa4690
Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220. doi:10.1038/nrd1657
Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8:423–435. doi:10.1038/nrmicro2333
Kotra LP, Haddad J, Mobashery S (2000) Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44:3249–3256. doi:10.1128/AAC.44.12.3249-3256.2000.Updated
Kramer NE, Smid EJ, Kok J et al (2004) Resistance of Gram-positive bacteria to nisin is not determined by Lipid II levels. FEMS Microbiol Lett 239:157–161. doi:10.1016/j.femsle.2004.08.033
Kretz J, Kerwat D, Schubert V et al (2015) Total synthesis of albicidin: A lead structure from xanthomonas albilineans for potent antibacterial gyrase inhibitors. Angew Chem Int Ed 54:1969–1973. doi:10.1002/anie.201409584
Kuipers OP, Rollema HS, de Vos WM, Siezen RJ (1993) Biosynthesis and secretion of a precursor of nisin Z by Lactococcus lactis, directed by the leader peptide of the homologous lantibiotic subtilin from Bacillus subtilis. FEBS Lett 330:23–27. doi:10.1016/0014-5793(93)80911-D
Kurosu M, Begari E (2010) Vitamin K2 in electron transport system: are enzymes involved in vitamin K2 biosynthesis promising drug targets? Molecules 15:1531–1553. doi:10.3390/molecules15031531
Kurosu M, Narayanasamy P, Biswas K et al (2007) Discovery of 1,4-didydroxy-2-naphthoate prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens. J Med Chem 50:3973–3975. doi:10.1021/jm070638m
Lapierre P, Gogarten JP (2009) Estimating the size of the bacterial pan-genome. Trends Genet 25:107–110. doi:10.1016/j.tig.2008.12.004
Lapuebla A, Abdallah M, Olafisoye O et al (2015a) Activity of imipenem with relebactam against gram-negative pathogens from New York City: Table 1. Antimicrob Agents Chemother 59:5029–5031. doi:10.1128/AAC.00830-15
Lapuebla A, Abdallah M, Olafisoye O, et al (2015b) Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:AAC.00843–15. doi:10.1128/AAC.00843-15
Lazarevic V, Karamata D (1995) The tagGH operon of Bacillus subtilis 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. Mol Microbiol 16:345–355. doi:10.1111/j.1365-2958.1995.tb02306.x
Lee K, Campbell J, Swoboda JG et al (2010) Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg Med Chem Lett 20:1767–1770. doi:10.1016/j.bmcl.2010.01.036
Lee SH, Wang H, Labroli M, et al (2016a) TarO-specific inhibitors of wall teichoic acid biosynthesis restore b -lactam efficacy against methicillin-resistant staphylococci. Sci Transl Med 8:329ra32. doi:10.1126/scitranslmed.aad7364
Lee W, Schaefer K, Qiao Y et al (2016b) The mechanism of action of lysobactin. J Am Chem Soc 138:100–103. doi:10.1021/jacs.5b11807
Leski TA, Tomasz A (2005) Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus. J Bacteriol 2:1815–1824. doi:10.1128/JB.187.5.1815
Leu FP, Hingorani MM, Turner J, O’Donnell M (2000) The δ subunit of DNA polymerase III holoenzyme serves as a sliding clamp unloader in Escherichia coli. J Biol Chem 275:34609–34618. doi:10.1074/jbc.M005495200
Lewis K (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov 12:371–387. doi:10.1038/nrd3975
Lim D, Strynadka NCJ (2002) Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 9:870–876. doi:10.1038/nsb858
Lin AH, Murray RW, Vidmar TJ, Marotti KR (1997) The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 41:2127–2131
Ling LL, Schneider T, Peoples AJ et al (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459. doi:10.1038/nature14098
Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28:352–364. doi:10.1086/515104
Littmann J, Buyx A, Cars O (2015) Antibiotic resistance: An ethical challenge. Int J Antimicrob Agents 46:359–361. doi:10.1016/j.ijantimicag.2015.06.010
Liu LF, Liu CC, Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19:697–707. doi:10.1016/S0092-8674(80)80046-8
Livermore DM, Warner M, Mushtaq S (2013) Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290. doi:10.1093/jac/dkt178
Livermore DM, Mushtaq S, Warner M, Woodford N (2015) Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother 70:3032–3041. doi:10.1093/jac/dkv239
Lowther GE (1979) The united states food and drug administration and the practice of optometry. J Am Optom Assoc 50:579–582
Lu X, Zhou R, Sharma I et al (2012) Stable analogues of OSB-AMP: potent Inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. ChemBioChem 13:129–136. doi:10.1002/cbic.201100585
Maki H, Yamaguchi T, Murakami K (1994) Cloning and characterization of a gene affecting the methicillin resistance level and the autolysis rate in Staphylococcus aureus. J Bacteriol 176:4993–5000
Maren TH (1976) Relatons between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 16:309–327. doi:10.1146/annurev.pa.16.040176.001521
Martin NI, Breukink E (2007) Expanding role of lipid II as a target for lantibiotics. Future Microbiol 2:513–525. doi:10.2217/17460913.2.5.513
Mast Y, Wohlleben W (2014) International Journal of Medical Microbiology Streptogramins – Two are better than one ! 304:44–50
Maxwell A (1993) The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 9:681–686. doi:10.1111/j.1365-2958.1993.tb01728.x
Maxwell A, Lawson DM (2003) The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 3:283–303. doi:10.2174/1568026033452500
Mayer C, Janin YL (2014) Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem Rev 114:2313–2342
Mccomas CC, Mccomas CC, Crowley BM et al (2003) Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions. J Am Chem Soc 125:9314–9315
Medini D, Donati C, Tettelin H et al (2005) The microbial pan-genome. Curr Opin Genet Dev 15:589–594. doi:10.1016/j.gde.2005.09.006
Meeske AJ, Sham L-T, Kimsey H et al (2015) MurJ and a novel lipid II flippase are required for cell wall biogenesis in Bacillus subtilis. Proc Natl Acad Sci U S A 112:6437–6442. doi:10.1073/pnas.1504967112
Meredith TC, Swoboda JG, Walker S (2008) Late-stage polyribitol phosphate wall teichoic acid biosynthesis in Staphylococcus aureus. J Bacteriol 190:3046–3056. doi:10.1128/JB.01880-07
Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15:e732–e739. doi:10.1016/j.ijid.2011.07.007
Miles TJ, Hennessy AJ, Bax B et al (2013) Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett 23:5437–5441. doi:10.1016/j.bmcl.2013.07.013
Miller EL (2002) The penicillins: a review and update. J Midwifery Women’s Heal 47:426–434. doi:10.1016/S1526-9523(02)00330-6
Mislin GL, Schalk IJ (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6:408–420. doi:10.1039/c3mt00359k
Mital A (2009) Synthetic nitroimidazoles: biological activities and mutagenicity relationships. Sci Pharm 77:497–520. doi:10.3797/scipharm.0907-14
Mizrahi V, Henrie RN, Marlier JF et al (1985) Rate-limiting steps in the DNA polymerase I reaction pathway. Biochemistry 24:4010–4018. doi:10.1021/bi00336a031
Mohammadi T, Karczmarek A, Crouvoisier M et al (2007) The essential peptidoglycan glycosyltransferase MurG forms a complex with proteins involved in lateral envelope growth as well as with proteins involved in cell division in Escherichia coli. Mol Microbiol 65:1106–1121. doi:10.1111/j.1365-2958.2007.05851.x
Mohammadi T, van Dam V, Sijbrandi R et al (2011) Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J 30:1425–1432. doi:10.1038/emboj.2011.61
Moreno M, Elgaher WAM, Herrmann J et al (2015) Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp. Synlett 26:1175–1178. doi:10.1055/s-0034-1380509
Morrison C (2015) Antibacterial antibodies gain traction. Nat Rev Drug Discov 14:737–738. doi:10.1038/nrd4770
Mullane KM, Gorbach S (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 9:767–777. doi:10.1586/eri.11.53
Münch D, Roemer T, Lee SH et al (2012) Identification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus. PLoS Pathog 8:1–11. doi:10.1371/journal.ppat.1002509
Münch D, Engels I, Müller A et al (2015) Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother 59:772–781. doi:10.1128/AAC.02663-14
Murai M, Kaji T, Kuranaga T et al (2015) Total synthesis and biological evaluation of the antibiotic lysocin E and its enantiomeric, epimeric, and N-demethylated analogues. Angew Chem Int Ed 54:1556–1560. doi:10.1002/anie.201410270
Nesme J, Simonet P (2015) The soil resistome: a critical review on antibiotic resistance origins, ecology and dissemination potential in telluric bacteria. Environ Microbiol 17:913–930. doi:10.1111/1462-2920.12631
Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335. doi:10.1021/np200906s
Nichols D, Cahoon N, Trakhtenberg EM et al (2010) Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol 76:2445–2450. doi:10.1128/AEM.01754-09
Nicolau DP (2008) Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9:23–37. doi:10.1517/14656566.9.1.23
Niiranen L, Lian K, Johnson KA, Moe E (2015) Crystal structure of the DNA polymerase III β subunit (β-clamp) from the extremophile Deinococcus radiodurans. BMC Struct Biol. doi:10.1186/s12900-015-0032-6
Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593–656. doi:10.1128/MMBR.67.4.593
Nöllmann M, Crisona NJ, Arimondo PB (2007) Thirty years of Escherichia coli DNA gyrase: From in vivo function to single-molecule mechanism. Biochimie 89:490–499. doi:10.1016/j.biochi.2007.02.012
Noufflard-Guy-Loé H, Berteaux S (1965) Rev Tuberc Pneumol 29:301–326
Novak R (2011) Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci 1241:71–81. doi:10.1111/j.1749-6632.2011.06219.x
Nowicka B, Kruk J (2010) Occurrence, biosynthesis and function of isoprenoid quinones. Biochim Biophys Acta Bioenerg 1797:1587–1605. doi:10.1016/j.bbabio.2010.06.007
O’Connell KMG, Hodgkinson JT, Sore HF et al (2013) Combating multidrug-resistant bacteria: Current strategies for the discovery of novel antibacterials. Angew Chem Int Ed 52:10706–10733. doi:10.1002/anie.201209979
O’Neill J (2015) Securing new drugs for future generations : the pipeline of antibiotics. Wellcome Trust, London
Oakley AJ, Prosselkov P, Wijffels G et al (2003) Flexibility revealed by the 1.85 Å crystal structure of the $β$ sliding-clamp subunit of Escherichia coli DNA polymerase III. Acta Crystallogr Sect D 59:1192–1199. doi:10.1107/S0907444903009958
Oliphant CM, Green GM (2002) Quinolones: a comprehensive review. Am Fam Physician 65:455–464
Opperman TJ, Nguyen ST (2015) Recent advances toward a molecular mechanism of efflux pump inhibition. Front Microbiol 6:1–16. doi:10.3389/fmicb.2015.00421
Ozawa K, Horan NP, Robinson A et al (2013) Proofreading exonuclease on a tether: the complex between the E. coli DNA polymerase III subunits α, ε, θ and β reveals a highly flexible arrangement of the proofreading domain. Nucleic Acids Res 41:5354–5367. doi:10.1093/nar/gkt162
Page MGP (2013) Siderophore conjugates. Ann N Y Acad Sci 1277:115–126. doi:10.1111/nyas.12024
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011) Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943–4960. doi:10.1128/AAC.00296-11
Paris L (2015) Report of the Antibiotics resistance project: antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development
Parmar A, Iyer A, Vincent CS et al (2016) Efficient total syntheses and biological activities of two teixobactin analogues. Chem Commun 52:6060–6063. doi:10.1039/C5CC10249A
Payne DJ, Gwynn MN, Holms DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challanges of antibacterial discovery. Nat Rev Drug Discov 6:29–40
Pelchovich G, Omer-Bendori S, Gophna U (2013) Menaquinone and iron are essential for complex colony development in Bacillus subtilis. PLoS ONE 8:1–14. doi:10.1371/journal.pone.0079488
Pendleton JN, Gorman SP, Gilmore BF (2013) Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297–308. doi:10.1586/eri.13.12
Pereira MP, Schertzer JW, D’Elia MA et al (2008) The wall teichoic acid polymerase TagF efficiently synthesizes poly(glycerol phosphate) on the TagB product lipid III. ChemBioChem 9:1385–1390. doi:10.1002/cbic.200800026
Perez-Cruz C, Delgado L, Lopez-Iglesias C, Mercade E (2015) Outer-inner membrane vesicles naturally secreted by gram-negative pathogenic bacteria. PLoS ONE 10:1–18. doi:10.1371/journal.pone.0116896
Perry JA, Westman EL, Wright GD (2014) The antibiotic resistome: what’ s new? Curr Opin Microbiol 21:45–50. doi:10.1016/j.mib.2014.09.002
Peterson LR (2009) Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 49:992–993. doi:10.1086/605540
Piddock LJV (2012) The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis 12:249–253. doi:10.1016/S1473-3099(11)70316-4
Piddock LJV (2015) Teixobactin, the first of a new class of antibiotics discovered by ichip technology? J Antimicrob Chemother 70:2679–2680. doi:10.1093/jac/dkv175
Piel J (2010) Biosynthesis of polyketides by trans-AT polyketide synthases. Nat Prod Rep 27:996–1047. doi:10.1039/b816430b
Pinho MG, Errington J (2005) Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates. Mol Microbiol 55:799–807. doi:10.1111/j.1365-2958.2004.04420.x
Pinho MG, de Lencastre H, Tomasz A (2001) An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci USA 98:10886–10891. doi:10.1073/pnas.191260798
Policy IP (2010) The 10 × ‘20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081–1083. doi:10.1086/652237
Polz MF, Alm EJ, Hanage WP (2013) Horizontal gene transfer and the evolution of bacterial and archaeal population structure. Trends Genet 29:170–175. doi:10.1016/j.tig.2012.12.006
Powers JH (2003) Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis 16:547–551. doi:10.1097/01.qco.0000104294.87920.b4
Projan SJ (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6:427–430. doi:10.1016/j.mib.2003.08.003
Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792–821. doi:10.1128/CMR.00033-13
Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117–128. doi:10.1038/nrd3013
Rawat D, Nair D (2010) Extended-spectrum beta-lactamases in gram negative bacteria. J Glob Infect Dis 2:263–274. doi:10.4103/0974-777X.68531
Reck F, Alm RA, Brassil P et al (2012) Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: antibacterial agents with an improved safety profile. J Med Chem 55:6916–6933. doi:10.1021/jm300690s
Redgrave LS, Sutton SB, Webber MA, Piddock LJV (2014) Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22:438–445. doi:10.1016/j.tim.2014.04.007
Rex JH (2014) ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12:231–232. doi:10.1038/nrmicro3245
Robinson A, Causer RJ, Dixon NE (2012) Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr Drug Targets 13:352–372. doi:10.2174/138945012799424598
Roca J, Wang JC (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833–840. doi:10.1016/0092-8674(92)90558-T
Roca J, Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77:609–616. doi:10.1016/0092-8674(94)90222-4
Roca J, Berger JM, Harrison SC, Wang JC (1996) DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Proc Natl Acad Sci U S A 93:4057–4062. doi:10.1073/pnas.93.9.4057
Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Blázquez J (2013) Antibiotics and antibiotic resistance: A bitter fight against evolution. Int J Med Microbiol 303:293–297. doi:10.1016/j.ijmm.2013.02.004
Royer M, Costet L, Vivien E et al (2004) Albicidin pathotoxin produced by Xanthomonas albilineans is encoded by three large PKS and NRPS genes present in a gene cluster also containing several putative modifying, regulatory, and resistance genes. Mol Plant Microbe Interact 17:414–427
Saha R, Saha N, Donofrio RS, Bestervelt LL (2013) Microbial siderophores: a mini review. J Basic Microbiol 53:303–317. doi:10.1002/jobm.201100552
Sanchez S, Demain AL (eds) (2015) Antibiotics: current innovations and future trends. Caister Academic Press, Norfolk
Sauvage E, Kerff F, Terrak M et al (2008) The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 32:234–258. doi:10.1111/j.1574-6976.2008.00105.x
Savoia D (2012) Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiol 7:979–990. doi:10.2217/fmb.12.68
Schäberle TF, Lohr F, Schmitz A, König GM (2014) Antibiotics from myxobacteria. Nat Prod Rep 31:953. doi:10.1039/c4np00011k
Schaefer B (2014) Natural Products in the Chemical Industry. Springer, Berlin & Heidelberg
Schoeffler AJ, Berger JM (2008) DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 41:41–101. doi:10.1017/S003358350800468X
Schoepp-Cothenet B, Lieutaud C, Baymann F et al (2009) Menaquinone as pool quinone in a purple bacterium. Proc Natl Acad Sci U S A 106:8549–8554. doi:10.1073/pnas.0813173106
Schueffler A, Anke T (2014) Fungal natural products in research and development. Nat Prod Rep 1425–1448. doi:10.1039/C4NP00060A
Schwartz B, Markwalder JA, Wang Y (2001) Lipid II: total synthesis of the bacterial cell wall precursor and utilization as a substrate for glycosyltransfer and transpeptidation by penicillin binding protein (PBP) 1b of Eschericia coli. J Am Chem Soc 123:11638–11643. doi:10.1021/ja0166848
Schwechheimer C, Kuehn MJ (2015) Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol 13:605–619. doi:10.1038/nrmicro3525
Scott LJ (2013) Fidaxomicin: a review of its use in patients with clostridium difficile infection. Drugs 73:1733–1747. doi:10.1007/s40265-013-0134-z
Scott CP, Abel-Santos E, Wall M et al (1999) Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A 96:13638–13643. doi:10.1073/pnas.96.24.13638
Sewell EWC, Brown ED (2014) Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics. J Antibiot 67:43–51. doi:10.1038/ja.2013.100
Shahul HP, Solapure S, Mukherjee K et al (2014) Optimization of pyrrolamides as mycobacterial gyrb atpase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother 58:61–70. doi:10.1128/AAC.01751-13
Sham L-T, Butler EK, Lebar MD et al (2014) MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science 345:220–222
Sharma M, Chauhan PM (2012) Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges. Future Med Chem 4:1335–1365. doi:10.4155/fmc.12.68
Shiva F (2015) Antibiotic prescription and bacterial resistance. Arch Pediatr Infect Dis 3:e21540. doi:10.5812/pedinfect.21540
Silver LL (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6:41–55. doi:10.1038/nrd2202
Singh GS (2004) β-Lactams in the new millennium. Part-I : monobactams and carbapenems. Med Chem (Los Angeles) 4:62–92
Smillie C, Garcillan-Barcia MP, Francia MV et al (2010) Mobility of plasmids. Microbiol Mol Biol Rev 74:434–452. doi:10.1128/MMBR.00020-10
Spellberg B, Powers JH, Brass EP et al (2004) Trends in antimicrobial drug development: implications for the future 90502:1279–1286
Stadler M, Hoffmeister D (2015) Fungal natural products-the mushroom perspective. Front Microbiol 6:1–4. doi:10.3389/fmicb.2015.00127
Storm DR, Strominger JL (1974) Binding of bacitracin to cells and protoplasts of Micrococcus lysodeikticus. J Biol Chem 249:1823–1827
Stukenberg PT, Studwell-Vaughan PS, O’Donnell M, O’Donnell M (1991) Mechanism of the sliding beta-clamp of DNA polymerase III holoenzyme. J Biol Chem 266:11328–11334. doi:10.1074/jbc.M111.338145
Su X-H, Wang B-X, Le W-J et al (2016) Multidrug-resistant neisseria gonorrhoeae Isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother 60:621–623. doi:10.1128/AAC.01211-15
Swoboda JG, Meredith TC, Cambell J et al (2010) Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Stphylococcus aureus. ACS Chem Biol 5:839–849
Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S (2011) Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosynthesis in Staphylococcus aureus. ACS Chem Biol 6:106–116
Syvanen M (2012) Evolutionary implications of horizontal gene transfer. Annu Rev Genet 46:341–358. doi:10.1146/annurev-genet-110711-155529
Tari LW, Li X, Trzoss M et al (2013) Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. PLoS ONE 8:e84409. doi:10.1371/journal.pone.0084409
Taubes G (2008) The bacterial fight back. Science 321:356–361
Tegos GP, Haynes M, Strouse JJ et al (2011) Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des 17:1291–1302. doi:10.1038/nature11130.Reduced
Terlain B, Thomas JP (1969) C R Hebd Seances Acad Sci Ser C 269:1546–1549
Terlain B, Thomas JP (1971a) Bull Chim Soc Fr 6:2349–2356
Terlain B, Thomas JP (1971b) Bull Chim Soc Fr 6:2357–2362
Tettelin H, Riley D, Cattuto C, Medini D (2008) Comparative genomics: the bacterial pan-genome. Curr Opin Microbiol 11:472–477. doi:10.1016/j.mib.2008.09.006
‘t Hart P, Oppedijk SF, Breukink E, Martin NI (2016) New insights into nisin’s antibacterial mechanism revealed by binding studies with synthetic lipid II analogues. Biochemistry 55:232–237. doi:10.1021/acs.biochem.5b01173
Thaker M, Spanogiannopoulos P, Wright GD (2010) The tetracycline resistome. Cell Mol Life Sci 67:419–431. doi:10.1007/s00018-009-0172-6
Tommasi R, Brown DG, Walkup GK et al (2015) ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14:529–542. doi:10.1038/nrd4572
Torres C (2010) Up against the wall. Nat Med 16:628–631. doi:10.1038/nm0610-628
Toussaint KA, Gallagher JC (2015) β-Lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86–98. doi:10.1177/1060028014556652
Upadhyay A, Upadhyaya I, Kollanoor-Johny A, Venkitanarayanan K (2014) Combating pathogenic microorganisms using plant-derived antimicrobials: a minireview of the mechanistic basis. Biomed Res Int Article ID 761741. doi:10.1155/2014/761741
Uria-Nickelsen M, Neckermann G, Sriram S et al (2013) Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines. Int J Antimicrob Agents 41:363–371. doi:10.1016/j.ijantimicag.2012.12.001
Venter H, Mowla R, Ohene-Agyei T, Ma S (2015) RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 6:377. doi:10.3389/fmicb.2015.00377
Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. P & T 40:277–283
Vivien E, Pitorre D, Cociancich S et al (2007) Heterologous production of albicidin: a promising approach to overproducing and characterizing this potent inhibitor of DNA gyrase. Antimicrob Agents Chemother 51:1549–1552. doi:10.1128/AAC.01450-06
Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440. doi:10.1038/nrm831
Wang H, Gill CJ, Lee SH et al (2013) Discovery of wall teichoic acid inhibitors as potential anti-MRSA beta-lactam combination agents. Chem Biol 20:272–284. doi:10.1016/j.chembiol.2012.11.013
Wang W, Qiu Z, Tan H, Cao L (2014) Siderophore production by actinobacteria. Biometals 27:623–631. doi:10.1007/s10534-014-9739-2
Watanakunakorn C (1984) Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 14:7–18. doi:10.1093/jac/14.suppl_D.7
Wattal C, Goel N (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9:894–896. doi:10.1038/nrmicro2693
Whitman WB, Coleman DC, Wiebe WJ (1998) Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 95:6578–6583. doi:10.1073/pnas.95.12.6578
Wiedemann I, Breukink E, Van Kraaij C et al (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772–1779. doi:10.1074/jbc.M006770200
Wijffels G, Dalrymple BP, Prosselkov P et al (2004) Inhibition of protein interactions with the beta 2 sliding clamp of Escherichia coli DNA polymerase III by peptides from beta 2-binding proteins. Biochemistry 43:5661–5671. doi:10.1021/bi036229j
Wijffels G, Johnson WM, Oakley AJ et al (2011) Binding inhibitors of the bacterial sliding clamp by design. J Med Chem 54:4831–4838. doi:10.1021/jm2004333
Williams DH, Bardsley B (1999) The vancomycin group of antibiotics and the fight against resistant bacteria. Angew Chem Int Ed 38:1172–1193. doi:10.1002/(SICI)1521-3773(19990503)38:9<1172:AID-ANIE1172>3.0.CO;2-C
Wolff P, Amal I, Oliéric V et al (2014) Differential modes of peptide binding onto replicative sliding clamps from various bacterial origins. J Med Chem 57:7565–7576. doi:10.1021/jm500467a
Wright GD (2007) The antibiotic resistome: the nexus of chemical and genetic diversity. NatRevMicrobiol 5:175–186. doi:10.1038/nrmicro1614
Wright GD (2010) The antibiotic resistome. Exp Opin Drug Disc 5:779–788. doi:10.1517/17460441.2010.497535
Wright GD (2012) The origins of antibiotic resistance. In: Coates ARM (ed) Handbook of experimental pharmacology, pp 45–65
Wright G (2015a) An irresistible newcomer. Nature 517:442–443. doi:10.1038/nature14193
Wright GD (2015b) Solving the antibiotic crisis. ACS Infect Dis 1:80–84. doi:10.1021/id500052s
Wright GD, Poinar H (2012) Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol 20:157–159. doi:10.1016/j.tim.2012.01.002
Wright PM, Seiple IB, Myers AG (2014) The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed 53:8840–8869. doi:10.1002/anie.201310843
Wyke AW, Ward JB, Hayes MV, Curtis NAC (1981) A role in vivo for penicillin-binding protein-4 of Staphylococcus aureus. Eur J Biochem 119:389–393. doi:10.1111/j.1432-1033.1981.tb05620.x
Xu Z-Q, Flavin MT, Flavin J (2014a) Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs 23:163–182. doi:10.1517/13543784.2014.848853
Xu Z-Q, Flavin MT, Flavin J (2014b) Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs 23:163–182. doi:10.1517/13543784.2014.848853
Yahav D, Farbman L, Leibovici L, Paul M (2011) Colistin: new lessons on an old antibiotic: EBSCOhost. Clin Microbiol Infect 18:18–29
Yin Z, Wang Y, Whittell LR et al (2014a) DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 21:481–487. doi:10.1016/j.chembiol.2014.02.009
Yin Z, Whittell LR, Wang Y et al (2014b) Discovery of lead compounds targeting the bacterial sliding clamp using a fragment-based approach. J Med Chem 57:2799–2806. doi:10.1021/jm500122r
Yin Z, Whittell LR, Wang Y et al (2015) Bacterial sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous linear motifs. J Med Chem 58:4693–4702. doi:10.1021/acs.jmedchem.5b00232
Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271–1272. doi:10.1128/aac.34.6.1271
Yoshida H, Bogaki M, Nakamura M et al (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647–1650. doi:10.1128/AAC.35.8.1647
Young IG (1975) Biosynthesis of bacterial menaquinones. Menaquinone mutants of Escherichia coli. Biochemistry 14:399–406. doi:10.1021/bi00673a029
Yunis AA (1988) Chloramphenicol: relation of structure to activity and toxicity. Annu Rev Pharmacol Toxicol 28:83–100 doi:10.1146/annurev.pa.28.040188.000503
Zaffiri L, Gardner J, Toledo-Pereyra LH (2012) History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 25:67–77. doi:10.3109/08941939.2012.664099
Zapun A, Philippe J, Abrahams KA et al (2013) In vitro reconstitution of peptidoglycan assembly from the gram-positive pathogen streptococcus pneumoniae. ACS Chem Biol 8:2688–2696. doi:10.1021/cb400575t
Zetts R (2014) Report of the Antibiotics resistance project: antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development
Zgurskaya HI, López CA, Gnanakaran S (2015) Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis 1:512–522. doi:10.1021/acsinfecdis.5b00097
Zhanel GG, Walkty AJ, Karlowsky JA (2015) Fidaxomicin: a novel agent for the treatment of clostridium difficile infection. Can J Infect Dis Med Microbiol 26:305–313
Zhang G, Meredith TC, Kahne D (2013) On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr Opin Microbiol 16:779–785. doi:10.1016/j.mib.2013.09.007
Zhao M, Goedecke T, Gunn J, et al (2013) Protostane and fusidane triterpenes: a mini-review. Molecules 18:4054–4080. doi:10.3390/molecules18044054
Acknowledgments
We thank Dr. Dr. Werner Tegge, Giambattista Testolin, Isabell Schneider and Dr. Verena Fetz for fruitful discussions and for proofreading of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Klahn, P., Brönstrup, M. (2016). New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development. In: Stadler, M., Dersch, P. (eds) How to Overcome the Antibiotic Crisis . Current Topics in Microbiology and Immunology, vol 398. Springer, Cham. https://doi.org/10.1007/82_2016_501
Download citation
DOI: https://doi.org/10.1007/82_2016_501
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-49282-7
Online ISBN: 978-3-319-49284-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)